Dodge & Cox 13F: Cuts Gilead Sciences (GILD) Stake by $256M
Dodge & Cox trimmed its position in Gilead Sciences by over 2 million shares.
Reviewed by automated data checks against the source filing. How we make and check alerts
Dodge & Cox sold 2,032,685 shares from its stake in Gilead Sciences, Inc. ($GILD), a 7.73% decrease, according to a 13F filing with the SEC dated May 14, 2026. It reported 24,250,826 shares worth $3.05 billion at the end of the quarter.
Since the filing, $GILD is down 1.2% after 1 week, down 5.3% after 1 month and up 19.7% to date (from the $130.46 close on May 14, 2026).
GILD
Gilead Sciences, Inc.
Key Points
- Dodge & Cox reduced its holdings in Gilead Sciences by 2,032,685 shares, a 7.7% decrease, now holding 24,250,826 shares.
- Gilead Sciences trades at $125.87 with a market cap of $154.66 billion and a P/E ratio of 16.95.
- The company offers a 2.61% dividend yield with a payout ratio of 43.4%.
Get $GILD trade alerts by text
We text you when insiders, Congress or big funds trade $GILD. Free.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated Gilead Sciences, Inc. alert may contain errors. Disclosures
Dodge & Cox has trimmed its stake in Gilead Sciences, Inc. (NasdaqGS: GILD), according to its latest 13F filing with the SEC. The fund reduced its holdings by 2,032,685 shares, a 7.7% decrease, leaving it with 24,250,826 shares valued at approximately $3.05 billion as of the end of the reporting period.
What Changed in Dodge & Cox's Gilead Sciences Position
Dodge & Cox reduced its investment in Gilead Sciences by over 2 million shares, bringing its total holdings down to 24.25 million shares. This reduction represents a 7.7% decrease from the previous 26.28 million shares. The move adjusted the fund's stake to a value of about $3.05 billion.
Gilead Sciences, Inc. Stock Down 20.0%
Shares of Gilead Sciences traded near $125.87 recently. The company has a market capitalization of approximately $154.66 billion and a P/E ratio of 16.95. Its forward P/E is 12.99, reflecting expectations of future earnings growth. Gilead's stock has a 52-week low of $104.46 and a high of $157.29. The 50-day moving average is $133.26, while the 200-day moving average stands at $129.10. The company maintains a current ratio of 1.967 and a quick ratio of 1.536, with a debt-to-equity ratio of 94.635.
Recent Earnings
Gilead Sciences reported revenue of $29.74 billion, with a growth rate of 4.4%. The company's net margin stands at 30.993%, and it has a return on equity of 43.36%. Its earnings per share (EPS) is $7.35. The next earnings report is expected on May 7, 2026.
Dividend
Gilead Sciences offers an annual dividend rate of $3.28, yielding 2.61%. The dividend payout ratio is 43.4%, indicating a solid distribution relative to earnings.
About Gilead Sciences
Gilead Sciences, Inc. is a biopharmaceutical company based in Foster City, California. It focuses on discovering, developing, and commercializing medicines for unmet medical needs. The company provides treatments for HIV, hepatitis, cancer, and other serious diseases. Led by CEO Daniel Patrick O'Day, Gilead employs around 17,000 people globally.
Bottom Line
Dodge & Cox's reduction of its Gilead Sciences position might indicate a rebalancing of its portfolio. Investors often track these filings to gauge institutional sentiment, but it's important to remember that 13F filings reflect past positions and may not represent current holdings.
Related Filing Alerts
Source: Dodge & Cox's 13F filing on $GILD (May 14, 2026). 13F filings show holdings as of the end of the reporting quarter and may not reflect the fund's current position. Find the original filing: Dodge & Cox 13F filings on SEC EDGAR. Written by software, not financial advice. How we make alerts